Effect of different HbA1c levels on the gut microbiota in patients with type 2 diabetes mellitus

Chen,Yanxia; Mou,Rongfei; Wang,Mian

doi:10.3892/wasj.2021.115

Effect of different HbA1c levels on the gut microbiota in patients with type 2 diabetes mellitus

Authors:
- Yanxia Chen
- Rongfei Mou
- Mian Wang
View Affiliations

Affiliations: Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: July 9, 2021 https://doi.org/10.3892/wasj.2021.115
Article Number: 44
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence indicates that the gut microbiota contributes to the development and progression of type 2 diabetes mellitus (T2DM). However, little is known about the effects of different hemoglobin A1c (glycated hemoglobin; HbA1c) levels on the gut microbiota. In the present study, the changes in microbial composition associated with different HbA1c levels in patients with T2DM were investigated. For this purpose, 30 patients with T2DM were randomly divided into three groups according to the HbA1c levels: Group A (HbA1c levels, ≥53 but <75 mmol/mol), group B (HbA1c levels, ≥75 but ≤97 mmol/mol) and group C HbA1c levels, >97.0 mmol/mol). 16S‑rDNA sequencing was performed to analyze the effects of different HbA1c levels on the gut microbiota. The results revealed that the microbial richness and inner diversity of the gut microbiome was slightly increased as the HbA1c levels increased. The Firmicutes/Bacteroidetes ratio was reduced with the increase in blood glucose levels. Collectively, the findings of the present study demonstrated that there was a certain association between the gut microbiome and HbA1c levels in patients with T2DM, indicating that modulating the microbial composition may be a potential strategy for improving glucose homeostasis.

View Figures

View References

1	Bordalo Tonucci L, Dos Santos KM, De Luces Fortes Ferreira CL, Ribeiro SM, De Oliveira LL and Martino HS: Gut microbiota and probiotics: Focus on diabetes mellitus. Crit Rev Food Sci Nutr. 57:2296–2309. 2017.PubMed/NCBI View Article : Google Scholar
2	Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M and Nageshwar Reddy D: Role of the normal gut microbiota. World J Gastroenterol. 21:8787–8803. 2015.PubMed/NCBI View Article : Google Scholar
3	Giambò F, Italia S, Teodoro M, Briguglio G, Furnari N, Catanoso R, Costa C and Fenga C: Influence of toxic metal exposure on the gut microbiota (Review). World Acad Sci J: Feb 2, 2021 (Epub ahead of print). doi: org/10.3892/wasj.2021.90.
4	Kalinkovich A and Livshits G: A cross talk between dysbiosis and gut-associated immune system governs the development of inflammatory arthropathies. Semin Arthritis Rheum. 49:474–484. 2019.PubMed/NCBI View Article : Google Scholar
5	Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J and Bäckhed F: Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 498:99–103. 2013.PubMed/NCBI View Article : Google Scholar
6	Bianchi F, Duque ALRF, Saad SMI and Sivieri K: Gut microbiome approaches to treat obesity in humans. Appl Microbiol Biotechnol. 103:1081–1094. 2019.PubMed/NCBI View Article : Google Scholar
7	Battson ML, Lee DM, Weir TL and Gentile CL: The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 56:1–15. 2018.PubMed/NCBI View Article : Google Scholar
8	Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, et al: Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 60:2775–2786. 2011.PubMed/NCBI View Article : Google Scholar
9	Brunkwall L and Orho-Melander M: The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: From current human evidence to future possibilities. Diabetologia. 60:943–951. 2017.PubMed/NCBI View Article : Google Scholar
10	Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, et al: Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 23:850–858. 2017.PubMed/NCBI View Article : Google Scholar
11	Su B, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P and Meng X: Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. 7:729–739. 2015.PubMed/NCBI View Article : Google Scholar
12	Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N and Lu Y: A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne). 9(233)2018.PubMed/NCBI View Article : Google Scholar
13	Liao X, Song L, Zeng B, Liu B, Qiu Y, Qu H, Zheng Y, Long M, Zhou H, Wang Y, et al: Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine. 44:665–674. 2019.PubMed/NCBI View Article : Google Scholar
14	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998.PubMed/NCBI View Article : Google Scholar
15	Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B, Pasić L, Thingstad TF, Rohwer F and Mira A: Explaining microbial population genomics through phage predation. Nat Rev Microbiol. 7:828–836. 2009.PubMed/NCBI View Article : Google Scholar
16	Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al: MetaHIT Consortium: A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464:59–65. 2010.PubMed/NCBI View Article : Google Scholar
17	Zhao L, Lou H, Peng Y, Chen S, Zhang Y and Li X: Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine. 66:526–537. 2019.PubMed/NCBI View Article : Google Scholar
18	Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrügger S, Mærkedahl RB, Bahl MI, Lind MV, Nielsen RL, Frøkiær H, et al: Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: A randomised cross-over trial. Gut. 68:83–93. 2019.PubMed/NCBI View Article : Google Scholar
19	Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH and Jakobsen M: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 5(e9085)2010.PubMed/NCBI View Article : Google Scholar
20	Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al: A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490:55–60. 2012.PubMed/NCBI View Article : Google Scholar
21	Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, Bell CJ and Shah VO: Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. 2:1–7. 2015.PubMed/NCBI View Article : Google Scholar
22	Huang Y, Li SC, Hu J, Ruan HB, Guo HM, Zhang HH, Wang X, Pei YF, Pan Y and Fang C: Gut microbiota profiling in Han Chinese with type 1 diabetes. Diabetes Res Clin Pract. 141:256–263. 2018.PubMed/NCBI View Article : Google Scholar
23	Ebrahimzadeh Leylabadlo H, Sanaie S, Sadeghpour Heravi F, Ahmadian Z and Ghotaslou R: From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 81(104268)2020.PubMed/NCBI View Article : Google Scholar
24	Dalile B, Vervliet B, Bergonzelli G, Verbeke K and Van Oudenhove L: Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: A randomized, placebo-controlled trial. Neuropsychopharmacology. 45:2257–2266. 2020.PubMed/NCBI View Article : Google Scholar
25	Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, Vieira AT, Kranich J and Mackay CR: Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 245:164–176. 2012.PubMed/NCBI View Article : Google Scholar
26	Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, et al: An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol. 29:1055–1066. 2015.PubMed/NCBI View Article : Google Scholar
27	Ørgaard A, Jepsen SL and Holst JJ: Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice. Islets. 11:103–111. 2019.PubMed/NCBI View Article : Google Scholar
28	Everard A and Cani PD: Gut microbiota and GLP-1. Rev Endocr Metab Disord. 15:189–196. 2014.PubMed/NCBI View Article : Google Scholar
29	Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, et al: Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 359:1151–1156. 2018.PubMed/NCBI View Article : Google Scholar
30	Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DS and Chaiyasut C: The influence of probiotics on bile acids in diseases and aging. Biomed Pharmacother. 128(110310)2020.PubMed/NCBI View Article : Google Scholar
31	Wahlström A, Sayin SI, Marschall HU and Bäckhed F: Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24:41–50. 2016.PubMed/NCBI View Article : Google Scholar
32	Higuchi S: The physiological importance of bile acid structure and composition on glucose homeostasis. Curr Diab Rep. 20(42)2020.PubMed/NCBI View Article : Google Scholar
33	Chávez-Talavera O, Tailleux A, Lefebvre P and Staels B: Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 152:1679–1694.e3. 2017.PubMed/NCBI View Article : Google Scholar
34	Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, et al: Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 6(7629)2015.PubMed/NCBI View Article : Google Scholar
35	Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, et al: TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167–177. 2009.PubMed/NCBI View Article : Google Scholar
36	Rajani C and Jia W: Bile acids and their effects on diabetes. Front Med. 12:608–623. 2018.PubMed/NCBI View Article : Google Scholar
37	González-Regueiro JA, Moreno-Castañeda L, Uribe M and Chávez-Tapia NC: The role of bile acids in glucose metabolism and their relation with diabetes. Ann Hepatol. 16 (Suppl 1: s3-105):16–21. 2017.PubMed/NCBI View Article : Google Scholar
38	Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T and Knop FK: Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications. 31:918–927. 2017.PubMed/NCBI View Article : Google Scholar
39	Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and Matthews DR: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38:140–149. 2015.PubMed/NCBI View Article : Google Scholar
40	Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK and Wu T: Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes Obes Metab. 22:141–148. 2020.PubMed/NCBI View Article : Google Scholar
41	Qiu Y, Shen L, Fu L, Yang J, Cui C, Li T, Li X, Fu C, Gao X, Wang W, et al: The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice. Diabetologia. 63:1002–1016. 2020.PubMed/NCBI View Article : Google Scholar
42	Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, et al: Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 8(1785)2017.PubMed/NCBI View Article : Google Scholar